Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease

Critical to development of new therapies for Alzheimer’s disease (AD) is the ability to detect clinical or pathological change over time. Clinical outcome measures typically used in therapeutic trials have unfortunately proven to be relatively variable and somewhat insensitive to change in this slow...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleisher, Adam S., Donohue, Michael, Chen, Kewei, Brewer, James B., Aisen, Paul S., the Alzheimer’s Disease Neuroimaging Initiative
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444278/
https://www.ncbi.nlm.nih.gov/pubmed/19847051
http://dx.doi.org/10.3233/BEN-2009-0241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444278/
https://www.ncbi.nlm.nih.gov/pubmed/19847051
http://dx.doi.org/10.3233/BEN-2009-0241

Ejemplares similares